Serum Institute has conducted the phase 1, 2 and 3 clinical trials of the vaccine in India and African nation Gambia. (REUTERS)
NEW DELHI : The first indigenous vaccine against pneumonia, developed by Serum Institute of India (SII), is slated to be launched by Union Health Minister Harsh Vardhan and made available in the domestic market early next week, official sources said on Wednesday.
According to the sources, the vaccine will be much more affordable than existing ones manufactured by two foreign companies.
India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm.
This vaccine is used for active immunisation against invasive disease and pneumonia caused by "Streptococcus pneumonia" in infants, the health ministry had said earlier.
Serum Institute has conducted the phase 1, 2 and 3 clinical trials of the vaccine in India and African nation Gambia.
"This is the first indigenously developed vaccine in the field of pneumonia," an official source said.
The vaccine will be much more affordable than existing ones produced by Pfizer (NYSE: PFE) and GlaxoSmithKline (LSE: GSK), the sources said.
"It has always been our endeavour to fulfil our prime minister's dream for 'vocal for local' and 'Making in India' for the world."Moving towards prime minister's clarion call of Atmanirbhar Bharat, we have achieved one more historical milestone during the lockdown period of COVID-19 pandemic by developing India's first world-class indigenous pneumococcal conjugate vaccine (PCV) and obtained Indian licensure," stated a letter written by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at Serum Institute of India (SII) addressed to Vardhan.
As per UNICEF data, more than one lakh children under the age of five years die every year in India due to the pneumococcal disease.Since pneumonia is a respiratory ailment, hence vaccination of children with the pneumococcal conjugate vaccines (PCV) assumes utmost significance during the current COVID-19 pandemic, an official source said.
The country is currently dependent on imported PCV of foreign manufacturers at a very high price, the source said.
The vaccine which is administered in an intramuscular manner was prequalified by WHO in January.
Earlier, the demand of such vaccine was substantially met by licensed importers in the country since the manufacturers were all vaccine companies based outside India, the health ministry had earlier said.
Source - LiveMint
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.